• Poster presentation features the interim data from an ongoing Phase 1b clinical trial of TU2218 plus Keytruda combination therapy in patients with advanced solid tumors
• A 40% overall response rate (ORR) and 100% disease control rate (DCR) were achieved in high-dose cohort (195 mg/day)
• TU2218 was well-tolerated as a monotherapy and combination therapy with pembrolizumab, with no dose limiting toxicities (DLTs) to date

BOSTON and SEONGNAM, South Korea, June 1, 2024 /PRNewswire/ — TiumBio Co., Ltd. (Kosdaq: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for patients with rare and incurable diseases, announced interim results from the Phase 1b clinical trial of TU2218 in combination with pembrolizumab at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

TU2218 is a novel oral dual inhibitor targeting transforming growth factor beta receptor 1 (TGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2). TGF-ß and VEGF pathways in tumor microenvironment interfere with the anti-tumor activity of immune checkpoint inhibitors, so TU2218 is expected to maximize the efficacy of immuno-therapies by inhibiting them.

TiumBio’s ongoing Phase 1b clinical trial (NCT05784688) in the United States evaluates safety, pharmacokinetics, and preliminary efficacy of TU2218 in combination with Keytruda (pembrolizumab) in patients with advanced solid tumors. The study consists of three dosage groups (105 mg, 150 mg, and 195 mg/day), and the presentation at the ASCO Annual Meeting included results from 12 patients across the three cohorts. Data from the full Phase 1b trial, which includes 18 patients, will be available in the second half of 2024.

In the poster released at the 2024 ASCO Annual Meeting, five patients treated at the recommended phase 2 dose (RP2D) of 195mg/day TU2218 in combination with pembrolizumab demonstrated an ORR of 40% at PR (n=2) and 60% at SD (n=3) with a DCR of 100%. And across all dosage groups, patients (n=12) receiving the combination therapy showed PR at 16.7% (n=2), SD at 50.0% (n=6) and PD at 25.0% (n=3). In this study, TU2218 was well-tolerated as a combination therapy with pembrolizumab, showing no signs of DLTs, which is consistent with a previous monotherapy trial.

“We are encouraged by the preliminary efficacy results with a favorable safety profile in patients with advanced tumors and are looking forward to top-line data from the study, which is expected in the second half of this year,” said Hun-Taek Kim, Ph.D., MBA, CEO at TiumBio. “We plan to initiate a Phase 2a clinical trial in head and neck cancer, biliary tract cancer, and colorectal cancer to develop an innovative novel drug for patients with limited treatment options,” he added.

About TiumBio Co., Ltd.

TiumBio (Kosdaq: 321550) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for patients with rare and incurable diseases. Its mission is to expand the hope and happiness of mankind through our science. TiumBio boasts three leading pipeline assets: merigolix (code name: TU2670), TU2218, and TU7710, all in various stages of clinical development.

Merigolix is a once-daily, oral GnRH receptor antagonist being developed for the treatment of endometriosis and uterine fibroids and is undergoing in global Phase 2 clinical trials. TU2218 is a first-in-class oral immune-oncology therapy targeting TGF-β and VEGF pathways to promote response rates in cancer patients when used in combination with immune checkpoint inhibitors. TU7710 is a novel rFVIIa designed to extend its half-life in order to provide more clinical benefits to hemophilia patients with inhibitors.

With its expertise in drug development, TiumBio is committed to the discovery and development of innovative treatments to ease the burden of debilitating diseases. For further information, visit our website at www.tiumbio.com/en and connect with us on LinkedIn.

Contacts:

Junseok Jang, Head of Corporate Communications & Investor Relations

junseokjang@tiumbio.com 

Suna Cho, Manager, Corporate Communications & Investor Relations

sunacho@tiumbio.com 

Da-ye Song, Manager, Corporate Communications & Investor Relations

dayesong@tiumbio.com

Source

SEOUL, South Korea, May 31, 2024 /PRNewswire/ — On May 27, 2024, the 8^th China-Japan-South Korea Business Summit convened in Seoul, South Korea, highlighted by a delegation led by Ren Hongbin, Chairman of the China Council for the Promotion of International Trade. The program featured the China-South Korea Economic Exchange Meeting and the 2^nd China International Supply Chain Expo (CISCE) Roadshow, which attracted over 200 representatives from various business associations and companies from the two countries.

China International Exhibition Center, the event’s organizer, signed the Memorandums of Understanding for the 2^nd CISCE with the South Korea-China Private Sector Economic Cooperation Forum and the World Electric Vehicle Association (WEVA).

Mr. Ren emphasized the robust economic and trade cooperation between China and South Korea, describing it as the bedrock of bilateral relations and essential for practical cooperation between the two nations. He expressed China’s eagerness to strengthen business connections, particularly in emerging sectors, such as the digital economy, green development, high-end manufacturing, biomedicine, and artificial intelligence (AI). He warmly welcomed South Korean firms to join the upcoming Expo in November.

Mr. Xing Haiming, Chinese Ambassador to South Korea, underscored the vital and indispensable role of efficient and resilient industrial and supply chains amid the ongoing process of globalization. He expressed optimism for future collaboration between two countries in exploring opportunities in green energy, the digital economy, and other burgeoning sectors.

Mr. Lee In-ho, Vice President of the Korea International Trade Association (KITA), remarked on the substantial growth of two countries. He stressed the importance of leveraging their existing economic and trade cooperation to jointly pursue opportunities in advanced technologies.

Ms. Yoo Myung-hee, former Trade Minister at South Korea’s Ministry of Trade, Industry, and Energy, spotlighted the critical need for stabilizing and managing the interconnected supply chains between the two countries in today’s economic climate. She called for enhanced communication channels and increased resilience against disruptions to the supply chain.

Mr. Ji Yong-mo, Chairman of the South Korea-China Private Sector Economic Cooperation Forum, praised the achievements of the South Korea-China Private Sector Economic Cooperation Forum in organizing member companies to participate in the inaugural CISCE last year. He reaffirmed the Forum’s unwavering commitment to fully support the upcoming the 2^nd edition of CISCE.

The second CISCE will be held in Beijing from 26^th-30^th November this year. Please visit https://en.cisce.org.cn/ for more information.

Source

In the news release, GIGABYTE AI New Era: Humanity X Art X Technology Exhibition, issued 31-May-2024 by GIGABYTE over PR Newswire, the 3rd item in the numbered list should read “AI Applications Featuring RTX AI PCs” rather than “AI Applications Featuring RTX -AI PCs” as incorrectly transmitted by PR Newswire. The complete, corrected release follows:

GIGABYTE AI New Era: Humanity X Art X Technology Exhibition

Embrace the Future with Computing Power! GIGABYTE AI PCs Lead You to Explore New Frontiers

TAIPEI, May 31, 2024 /PRNewswire/ — GIGABYTE is excited to present the “AI New Era” exhibition, showcasing how AI is transforming our world. This event explores AI-generated art, AI applications, and other immersive experiences that demonstrate the practical uses of AI PCs in everyday life.

Exhibition Themes

The “GIGABYTE AI New Era” exhibition features three thematic areas, each illustrating the diverse nature of AI:

1. AI Art: This area showcases dynamic images and interactive art created by international artists. Notable contributors include the Dimension + new media art team led by Escher Tsai (Taiwan) and Keith Lam (Hong Kong), Ygor Marotta from the VJ Suave studio in São Paulo, Brazil, and emerging Taiwanese artist Tim Wei. Attendees will embark on a sensory journey as these artists share their inner worlds and the collaborative process of integrating GIGABYTE AI PCs into  their work.
2. VS AI Street Battle: In collaboration with Hello World, this section challenges traditional art forms using the latest text-to-image AI applications. Utilizing GIGABYTE AI PCs’ powerful and stable computing capabilities, this area combines large-scale arcade fighting games with generative AI, creating a unique and creative battle system. 
3. AI Applications Featuring RTX AI PCs: This area explores how AI enhances everyday life across various fields, including gaming, digital art, content creation, image processing, and productivity. Guided by GIGABYTE AI PCs, consumers can experience limitless AI applications, seamlessly integrating AI into their daily routines. Emmy-nominated filmmaker Hugh Hou (US) will curate the AI Use Case zone, showcasing the latest AI technology and providing a professional workflow for creating immersive videos. Additionally, GIGABYTE will collaborate with NVIDIA to showcase a series of advanced AI applications featuring GeForce RTX graphics cards.

Invitation to All

GIGABYTE warmly welcomes technology enthusiasts and art connoisseurs to join this grand event and experience the revolution in technology and art brought by artificial intelligence. For more information about the event, please visit the official website: GIGABYTE AI 2024.

Join us in exploring the future of AI and its impact on our daily lives, and witness how GIGABYTE is leading the charge in integrating AI into the world of art and technology.

Source

SHANGHAI, May 31, 2024 /PRNewswire/ — Shanghai Grit Biotechnology Co., Ltd. (GRIT) and Shandong Quangang Pharmaceutical Co., Ltd. (Quangang) announced the establishment of a formal strategic partnership to leverage both parties’ R&D capabilities in innovative T-cell therapy. The objective is to jointly develop a globally standardized IL-2 for solid tumor patients receiving T-cell therapy, aiming to localize the global standard IL-2 with accessible prices for Chinese patients.

The focus of the collaboration will be on expanding the indications of Quanqi (125SER) Interleukin-2 (I) products for solid tumors. Quanqi (125SER), as a domestically marketed human Interleukin-2, is primarily used in the treatment of solid tumors such as renal cell carcinoma, melanoma, breast cancer, bladder cancer, liver cancer, colorectal cancer, lymphoma, and lung cancer, etc. Both parties will collaborate to develop a domestically produced substitute to the globally recognized immune-regulating cytokine IL-2 in T-cell therapy, addressing the significant unmet medical needs for Chinese cancer patients.

Grit is a clinical stage cell therapy company leading the tumor infiltrating lymphocytes (TILs) therapy development in China. Grit’s non-gene-engineered TIL program GT101 is in Phase 2 (pivotal) trial — it is the fastest TIL pipeline in China and plans for BLA filing in 2025. Quangang Pharmaceutical is a leading domestic biopharmaceutical company dedicated to the research and development of genetic medicines, boasting GMP facilities and a specialized biotechnology research institute. Both parties have rich technical expertise and product development experience, along with a strong reputation and influence in the biopharmaceutical field in China.

Through this collaboration, GRIT will leverage its extensive experience in T cell therapy to expedite the advancement and commercialization of cell therapy products, providing a broader range of options and instilling hope for a greater number of solid tumor patients in the Chinese market. Both parties affirm that through their joint efforts, there is anticipation for a broader spectrum of Chinese patients to soon gain access to advanced and efficacious T-cell treatment options with the affordable local IL-2 product.

Source

SHANGHAI, May 31, 2024 /PRNewswire/ — Currently, AIGC (AI-Generated Content) has caught on in the market and among the general public. The constant arrival of new AI products such as ChatGPT, Sora and Suno has pushed this wave of technological change to the next level, making a sweeping impact on everyone. As always, technology development is about unlocking creativity, and AIGC is no exception.

AIGC is knocking on the door of a brave new world. How will it influence individuals in their professional and personal lives? And what opportunities are up for grabs?

In an attempt to answer these questions, Just So Soul, a research arm of the social platform Soul App (approximately 80% of its monthly active users are Gen Zers), surveyed Soul users about AIGC (approximately 80% of participants were Gen Zers). The survey received 3,457 valid responses, and three key takeaways were observed:

Over 90% of young people have used AIGC products, with those born in the 2000s being most knowledgeable about AIGC

Based on the White Paper on AI-Generated Content published by the China Academy of Information and Communications Technology, AIGC is a form of content, an approach to content production, and a set of automated content generation technologies.

However, the Just So Soul survey found that this academic concept is not well understood, and 70% of younger generations have a “limited understanding” of AIGC.

Even so, the concept has found its way into everyday life. AIGC products and functions are ubiquitous, both in the workplace and learning environments. For example, they support the one-click generation of marketing copy or meeting minutes.

According to the research, a mere 4.8% of young people have “never used” any AIGC application. In other words, more than 90% have experienced AIGC products or functions. Among them, text generation chatbots like ChatGPT are most popular (65.68%).

The post-00s (individuals born in the 2000s) stand at the forefront of the new technology trend, accounting for the largest share of respondents who “have learned about or tried an AIGC product” (28.71%) and who are “well-informed about AIGC, involved in related industries or research, or proficient at using AIGC products” (6.06%). The post-00s are also the most frequent users of such applications, with 19.95% utilizing AIGC tools daily.

In a way, Gen Zers could be considered as a new form of human being. Professor He Yanhong of Shanghai Jiao Tong University said, “As their neurological systems and mindsets are shaped by Internet technologies, Gen Z may mark a fresh beginning of humanity.”

60% of young people feel positive about AIGC, with over 10% having monetized it

What do young people think of the development of AIGC and the business opportunities that come with it?

Over 60% are sanguine about AIGC: 17.93% “appreciate” it and 45.32% “like” it. On the other side of the spectrum, 1.65% “dislike” it and 0.66% “hate” it.

When asked about why they like the technology, respondents cited “greater work efficiency” (62.78%), “more convenience in life” (54.09%), and “an entertaining, interesting experience” (53.91%). On the other hand, negative emotions stem from three major issues: jobs being lost to AIGC technology (42.86%); AIGC spawning the proliferation of low-quality content (38.1%); rising concerns over privacy and data security (20.3%).

Compared with a similar survey Just So Soul completed last July, its latest study sees a plunge in disapproving opinions and a jump in favorable impressions. It is evident that advances in AIGC technology and adoption have improved youths’ attitude towards AIGC.

Interestingly, young users are starting to generate income from AIGC. Data shows that 14.8% of respondents “have cashed in on AICG” and 43.35% have plans to do so.

Many professionals in advertising, art, and cultural communication have harnessed AIGC technology to make money, and a large portion of the post-00s (42.5%) plan to earn an income through AIGC tools.

60% of young users have experienced AI-powered social networking products, and one third are willing to befriend AI

Social interactions are an ideal scenario for the application of AIGC. Multimodal AIGC has enhanced human-computer interaction in an unprecedented way. Just So Soul discovered that 60% of the surveyed have used AI-powered social networking products before.

Generally, younger generations are open to engaging with AI: 70.35% take a neutral position, 17.99% like to communicate with chatbots, and only 12% are averse to AI interactions.

Why do young people talk to AI? 47.11% stated that it is fun to chat with, never causing an awkward silence or a dull moment. Moreover, chatbots give immediate feedback (45.66%), discuss any topic the user chooses (44.53%), and provide emotional companionship (43.73%).

Data shows that above 50% of young people believe that AIGC products could, or have the potential to, ease loneliness. Only 8% insist that AIGC is “not useful in dispelling feelings of loneliness”.

Significantly, 32.8% are willing, or even eager, to make friends with an AI. As in the sci-fi movie Her, where the protagonist develops a special bond with an AI operating system named Samantha, the evolution of AIGC technology has brought this concept closer to reality. In the here and now, smart social networks featuring the coexistence of humans and AI are starting to take shape.

Source

• Neurophet’s AI brain image analysis technology improves time and cost efficiency for drug development
• Aims to create business opportunities with global pharmaceutical companies

SEOUL, South Korea, May 31, 2024 /PRNewswire/ — Neurophet, an artificial intelligence (AI) solution company for brain disease, announced its participation in the annual BIO International Convention 2024 (BIO USA) which will run from June 3 to 6 in San Diego, U.S.

Neurophet will highlight its Imaging CRO (Contract Research Organization) service, which could be used in clinical trials for the treatment of Alzheimer’s disease, during this year’s BIO USA.

Neurophet’s imaging CRO service provides analysis of medical images, including MRI and PET scans obtained during clinical trials and biomarker identification, using brain MRI analysis software “Neurophet AQUA” and brain PET image analysis software “Neurophet SCALE PET,” which received 510(k) clearance from the US Food and Drug Administration (FDA).  

This service plays an important role in ensuring image data quality and compliance by providing consistent and reliable analysis results and is highly efficient in terms of time and cost. Also, it empowers pharmaceutical and biotech companies to increase the success rate of new drug development since it can be used in the entire clinical trial process of new drug development from determining the clinical patient group, analyzing efficacy and monitoring side effects.

Neurophet has signed an agreement with AriBio, a developer of treatments for neurodegenerative disorders, to support and joint research in the global phase 3 clinical trial of AR1001, an oral Alzheimer’s disease treatment.

“Many pharmaceutical companies are actively developing new drugs through partnerships with AI companies to overcome the limitations of existing drug development, and this trend will expand further in the future,” said CEO Jake Junkil Been of Neurophet. “Neurophet’s Imaging CRO service is expected to provide a significant opportunity for global pharmaceutical companies developing treatments for Alzheimer’s disease, since it holds great potential to contribute for successful clinical trials and to improve operational efficiency.”

He added, “Neurophet’s brain image analysis technology was explored by many participants, continuing to spark significant interest and engagement through various global exhibitions and business events, and we will do our best for meaningful partnerships as meetings with various global pharmaceutical companies are scheduled at this BIO USA.”

The BIO USA is the world’s largest event in the bio industry with pharmaceutical companies, bio companies, university research institutes, and investment companies attending for global partnering opportunities.

About Neurophet

Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain diseases based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Jake Junkil Been, CEO, and Donghyeon Kim, CTO, who developed the next-generation neuro-navigation system.

Major products include brain MRI analysis software “Neurophet AQUA”, brain PET image analysis (PET tracer deposition) software “Neurophet SCALE PET”, brain imaging treatment planning software for electric and magnetic brain stimulation “Neurophet tES/TMS LAB”.

Neurophet has set its top priority to helping patients suffering from brain diseases. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain’s health and pioneer solutions for brain diseases with AI technology.

Source

PENANG, Malaysia, May 31, 2024 /PRNewswire/ — QNET, a global leader in wellness and lifestyle focused direct selling, concluded the first of this year’s biannual flagship event, V-Malaysia 2024, on May 16 in the island of Penang in Malaysia. The five-day convention drew approximately 9,000 participants from over 30 countries, reaffirming its status as a major international event.

Amezcua e-Guard X Launch

V-Malaysia 2024: A Platform for Learning, Networking, and Innovation
This year’s V-Malaysia featured an extensive agenda filled with opportunities for learning, networking, and experiencing the latest in QNET’s wellness and lifestyle advancements. Highlights included the mega QNET product exhibition where the company showcased its range of premium products such as the HomePure range of home appliances, the Amezcua range of wellness products, the Bernhard H Mayer range of luxury Swiss watches and fine jewellery, and the LifeQode portfolio of nutritional products, among others.

Groundbreaking Product Launches
QNET unveiled several innovative new products at this year’s convention:

• Amezcua e-Guard X – An innovative solution designed to mitigate the health impacts associated with mobile radiation from everyday electronic devices, including smartphones, laptops, and televisions.
• HomePure Rayn – A showerhead that not just filters shower water but also has the Amezcua Resonance Technology (ART) to help boost energy. It also has an optional Vitamin C capsule which can help remove residual chlorine from the skin and an optional ACF (Activated Carbon Fiber) capsule which removes fine microorganisms.
• Bernhard H. Mayer Alto Watch – The new ceramic watches by the Swiss watch brand that is ideal for daily wear is available in two variations, black and white, for both men and women. The quartz watch has a unique wave pattern on its face, and has hands made of recycled steel.

Empowering the Global Network
The event featured numerous training and education sessions tailored for QNET’s global network of distributors. These sessions aimed to enhance their skills in direct selling and empower them to achieve greater success in their personal business endeavours.

Inspiring Moments
In an inspiring session, attendees were treated to a special appearance by award-winning Indian actor R. Madhavan. He shared his compelling journey and struggles within the competitive Indian film industry, offering a story of triumph that resonated deeply with the diverse international audience.

Commitment to Sustainability
To offset the event’s carbon footprint, QNET ensured the event was free of single-use plastic, promoted plant-based food options, and organised a tree-planting exercise in partnership with Malaysia’s JARING, the National Fisherman’s Association, as part of its ongoing Green Legacy global reforestation program.

At the conclusion of the event, Trevor Kuna, Chief Marketing Officer of QNET said, “This event is not just a convention; it is a celebration of our commitment to our distributors and customers worldwide. We look forward to another year of remarkable experiences and success stories.”

ABOUT QNET
QNET, a global lifestyle and wellness company, uses a direct selling business model to promote unique products that enable people to take charge of their health, well-being, and lifestyle.

Since 1998, QNET’s innovative products and e-commerce-driven business model have helped build a global community of satisfied customers and microentrepreneurs, who are driven by the mission of RYTHM – Raise Yourself To Help Mankind. Popular product brands offered by QNET include the Bernhard H. Mayer range of luxury watches and jewellery, HomePure range of home care products, the Amezcua wellness range, Physio Radiance personal care range, and QVI branded holiday packages.

QNET proudly exemplifies high industry standards and is a member of numerous Direct Selling Associations worldwide. Its active engagement in several global sports sponsorships including in its role as the official direct selling partner of the Manchester City Football Club (MCFC) and the Confederation of African Football (CAF), highlights the company’s commitment to excellence.

Source

New 3D camera seamlessly integrates with SpatialLabs devices, streaming, and video calling platforms; Plus new developer tools made available on SpatialLabs Pro devices

Editor’s Summary:

• The Acer SpatialLabs Eyes Stereo Camera is designed for photographers, allowing them to capture and view stereoscopic images in immersive 3D with compatibility with Acer’s SpatialLabs suite of devices
• Features 8 megapixels (MP) per eye resolution, built-in selfie mirror, and weatherproof exterior, and offers auto and touch focus capabilities, Electronic Image Stabilization (EIS), and manual mode for more experienced photographers
• Enables real-time streaming, storytelling, and sharing of 3D content on various platforms, plus high-resolution 3D video calling on Teams, Zoom, and Google Meet
• The Acer SpatialLabs Eyes Stereo Camera has been awarded the 2024 RedDot and iF Design Awards for its innovative design, features, and usability

TAIPEI, May 31, 2024 /PRNewswire/ — Acer today launched the SpatialLabs Eyes Stereo camera, its latest addition to its range of SpatialLabs 3D devices. The compact 3D camera can be used by photographers to capture stunning and stereoscopic images and view these in immersive 3D as it fully integrates with the SpatialLabs lineup of products.

“The SpatialLabs Eyes Stereo Camera completes Acer’s stereoscopic 3D portfolio, providing solutions from content capturing and creation, to display and interaction,” said Jerry Kao, COO, Acer Inc. “We hope to empower users to capture the world around them in stunning stereoscopic 3D through the new camera and we’re excited to see the possibilities and the amazing content they will be able to create and share.”

Modern Design, Intuitive Point and Shoot Anywhere and Everywhere

With 8 megapixels per eye resolution, a built-in selfie mirror, and a weatherproof exterior, the pocket-sized Acer SpatialLabs Eyes Stereo Camera is a great companion for capturing moments in daily life. Its intuitive setup enhances shooting experiences with carefully calibrated lens alignment and an advanced optical system to photograph subjects with greater 3D depth and detail.

For effortless image taking, SpatialLabs Eyes is equipped with auto and touch focus capabilities, further enhanced with Electronic Image Stabilization (EIS) for smooth and steady footage. More seasoned photographers will appreciate the option for manual mode which provides flexibility to calibrate ISO, white balance, and shutter speed settings for better control of image output.

The camera’s outer material is glossed with a shale black coat, while its lens cap and selfie mirror enclosures are layered with aluminum lining to present a sophisticated look and feel. With its sleek appearance and innovative features, the Acer SpatialLabs Eyes Stereo Camera has earned the praise of design experts and received the prestigious 2024 Red Dot and iF Design Awards.

Beyond Snapshots: 3D Streaming and Video Calls in Real-time

The SpatialLabs 3D Camera goes beyond just capturing stunning images and videos in 3D. It enables real-time 3D streaming and storytelling, letting users share their 3D content live on YouTube and other streaming platforms with the new Acer SpatialLabs Player 3.0. Video chatting will be available through the SpatialLabs video call widget in Q3 that enables more engaging, high-resolution 3D video conferencing on apps such as Teams (1080p), Zoom (720p), and Google Meet (1080p), with customizable depth features available to add more layers of realism during calls.

Whether users are reviewing content on Acer SpatialLabs laptops or displays, VR/AR headsets, or even 3D projectors, the SpatialLabs Eyes helps present the richness and impact of their 3D content as intended. The camera also comes with a downloadable gallery feature so users can look back at their 3D portfolio and re-experience their immersive 3D journey.

New Range of Developer Tools for 3D Content and Applications

Acer has also announced an expanded array of developer tools, including the SpatialLabs Unreal 5.3 and Unity 2021.3 LTS and 2022.3 LTS plug-ins. These will be available to 3D creators starting in June.

In addition, the new SpatialLabs Model Viewer Pro application, which is fully compatible with SpatialLabs Pro devices, is also set to be launched. The application is designed to enhance the 3D content workflow and user experiences with new features tailored for commercial usability.

Paired with its support for major 3D file formats and enhanced support on glTF, the new presentation mode enables developers to inspect, customize, and showcase a catalog of models in sequence for viewing and customizations without the need to develop projects from scratch. The application includes features such as adding a virtual turntable, overlays with their desired logos, and backgrounds, as well as customizations with their preferred HDRI. This also makes it an ideal solution for 3D installations in showrooms and professional presentations. For more details, please visit the SpatialLabs developer site.

Pricing and Availability

The Acer SpatialLabs Eyes Stereo Camera (ASEC-1) will be available in North America in Q3, starting at USD 549, and in EMEA in Q3, starting at EUR 549.

Exact specifications, prices, and availability will vary by region. To learn more about availability, product specifications and prices in specific markets, please contact your nearest Acer office via www.acer.com.

Visit Acer’s Media Center for product images and specifications, or visit the Acer News site to see all announcements.

Specifications

About Acer

Founded in 1976, Acer is one of the world’s top ICT companies with a presence in more than 160 countries. As Acer evolves with the industry and changing lifestyles, it is focused on enabling a world where hardware, software and services will fuse with one another, creating ecosystems and opening up new possibilities for consumers and businesses alike. Acer’s 7,700 employees are dedicated to the research, design, marketing, sale, and support of products and solutions that break barriers between people and technology. Please visit www.acer.com for more information.

© 2024 Acer Inc. All rights reserved. Acer and the Acer logo are registered trademarks of Acer Inc. Other trademarks, registered trademarks, and/or service marks, indicated or otherwise, are the property of their respective owners. All offers subject to change without notice or obligation and may not be available through all sales channels. Prices listed are manufacturer suggested retail prices and may vary by location. Applicable sales tax extra.

Source